Patent 8198414 was granted and assigned to Medimmune Limited on June, 2012 by the United States Patent and Trademark Office.
Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumors associated with IL-6.